NCT06549790
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 11 versions: 10 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: The decision about study closure has not been based on safety profile or clinical data of NMS- 03597812 but for strategic decisions regarding the company's assets. Show 6 more changesShow less
- Eligibility criteria expanded, about 31 words
- Final enrollment: 23 participants (planned 124)
- Primary completion date changed from estimate of Sep 15, 2029 to Sep 24, 2026
- Study sites: 7 to 6
- Study completion date changed from estimate of May 15, 2030 to Oct 5, 2026
- Secondary endpoints: details revised at 4 of 22 entries
- Minor Site details revised at 1 of 7 sitesv10
- Minor Study sites: 6 to 7v9
- Minor Study sites: 4 to 6v7
- Minor Study sites: 3 to 4v6
Show 4 earlier versionsHide 4 earlier versions
- Minor Study sites: 2 to 3v5
- Minor Study sites: 1 to 2
- Start date changed from estimate of Oct 5, 2024 to Oct 16, 2024
- Notable Start date: Aug 2024 to Oct 5, 2024v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (22)
Show 17 moreShow less
Arms and interventions
Dose escalation (Phase Ia): Administered orally once daily (28 consecutive days) in repeated 4-week cycles. Each cycle is 28 days. Expansion cohorts (Phase Ib, Cohorts A and B): The dose expansion may comprise up to a total of 2 single arms of NMS-03597812 as single agent: * Cohort A: in patients with TP53mt relapsed/refractory acute myeloid leukemia (R/R AML) prior unfit to intensive chemotherapy (IC) who have exhausted standard treatment options * Cohort B: in prior fit or unfit patients to IC with TP53wt R/R AML who have exhausted standard treatment options Backfill cohorts: Optional backfill cohorts may be opened at any time during the conduct of the trial to further evaluate the following items: NMS-03597812 dosing alone, pharmacokinetic (PK), drug-drug interactions, food effects, biomarkers and QTc for NMS-03597812 as single agent.
Drugs: NMS-03597812
Sites
6 sites in 1 country